Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Masimo stock pops as appeals court reinstates Apple Watch sales ban

Published 01/17/2024, 03:02 PM
Updated 01/17/2024, 03:04 PM
© Reuters Masimo (MASI) stock pops as appeals court reinstates Apple Watch sales ban
AAPL
-
MASI
-

The Apple (NASDAQ:AAPL) Watch Series 9 and Apple Watch Ultra 2 – the two models equipped with blood oxygen features – face another sales ban in the United States, effective as of 5:00 pm ET on January 18, 2024.

The US Court of Appeals for the Federal Circuit has rejected Apple's plea to temporarily halt the ban during its appeal against the International Trade Commission's (ITC) decision that the devices violate two patents owned by medical device company Masimo (NASDAQ:MASI).

Shares of Massimo were up over 1.5% at the time of writing Wednesday.

Despite the ban, Apple is expected to continue selling the affected models, namely the Apple Watch Ultra 2 and Apple Watch Series 9. To comply with the ruling, Apple will likely release a firmware update to disable the blood oxygen feature on newly sold Apple Watches within the US.

This modification will exclusively apply to devices sold after the specified effective date.

The decision comes days after the US appeals court affirmed two prior rulings by a patent tribunal that sided with Masimo in its intellectual property dispute with Apple over blood oxygen sensors in newer Apple Watch models.

Latest comments

Corporate thrives. Jobs turning over in his grave.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.